A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months

Trial Profile

A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Meningococcal vaccine group C conjugate; Tick-borne encephalitis vaccine
  • Indications Encephalitis; Influenza virus infections; Meningococcal group C infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Aug 2012 Additional locations [Belgium, Hungary, Italy] identified as reported by as reported by European Clinical Trials Database(Parent trial: EudraCT2007-003786-41).
    • 07 Aug 2012 Additional locations [Belgium, Hungary, Italy] identified as reported by as reported by European Clinical Trials Database(Parent trial: EudraCT2007-003786-41).
    • 25 Feb 2012 Planned patient number 1970 added as reported by European Clinical Trials Database (Extention trial: EudraCT2010-021644-18).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top